108. TNF受容体関連周期性症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 5 / 薬物数 : 5 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 43

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ACZ885
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
ACZ885D
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
Canakinumab
   NOVARTIS FARMA
      2010   -   EUCTR2010-020061-24-IT   Ireland;Italy;United Kingdom
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Ilaris
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom
   Novartis Pharmaceuticals
      2025   -   NCT06838143   -
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Recombinant human monoclonal antibody TO human IL-1beta OF THE IGG1/K class
   Novartis Pharma Services AG
      2010   -   EUCTR2010-020061-24-IE   Ireland;Italy;United Kingdom
      2010   Phase 2   EUCTR2010-020061-24-GB   Ireland;Italy;United Kingdom